Entering text into the input field will update the search result below

Glycobiology Market Worth USD 2.0 Billion : Technological Advancements In The Field Of Proteomics And Glycomics Research

Dec. 01, 2021 3:39 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2014

#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology

Summary

  • Market Dynamics.
  • Some key players mentioned in the research report are.

The global glycomics market is estimated to grow from USD 1.0 billion in 2020 to USD 2.0 billion by 2025, at a CAGR of 13.8%.

Glycobiology MarketThis study involved four major activities in estimating the current size of the glycomics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

  • Increasing R&D Expenditure and Funding for Proteomics and Glycomics Research
  • Growth of the Proteomics Market
  • Technological Advancements in Glycomics Instrumentation

The market is categorized into five product segments, namely, enzymes, instruments, kits, carbohydrates, and reagents & chemicals. The enzymes segment is expected to dominate the market in 2020 and is projected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

Based on application, the glycomics market is segmented into drug discovery & development, disease diagnostics, and other applications. Drug discovery & development is the largest and the fastest-growing application segment in the market, majorly due to the increasing R&D investments in pharmaceutical and biotechnology companies and the growing number of drug discovery research activities in academic research institutes.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. RoW5. Middle East & Africa

The global glycomics market is segmented into North America (US and Canada), Europe (Germany, the UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, Australia, and the Rest of Asia Pacific), and the Rest of the World (Latin America and the Middle East and Africa). In 2020, North America is expected to dominate the global market, followed by Europe. The largest share of North America is mainly attributed to increasing investments in glycomics research, rising R&D investments in pharmaceutical companies for drug discovery and the presence of all key players.

Request Sample Pages @ Sample Request - Glycomics Market Size, Share and Trends forecast to 2025 by Product, Instruments, Application | COVID-19 Impact Analysis | MarketsandMarkets™

Some key players mentioned in the research report are:

The prominent players operating in the glycomics market include Merck KGaA (Germany), Agilent Technologies (US), Thermo Fisher Scientific (US), New England Biolabs (US), Shimadzu Corporation (Japan), Takara Bio (Japan), S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Waters Corporation (US), Asparia Glycomics S.L. (Spain), Bio-Techne (US), Bruker Corporation (US), Danaher Corporation (US), RayBiotech (US), Z Biotech (US), Chemily Glycoscience (US), Dextra Laboratories (UK), Lectenz Bio (US), and Ludger Ltd. (UK)

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.